{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T13:42:52Z","timestamp":1778593372402,"version":"3.51.4"},"reference-count":73,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1097\/pap.0b013e31828d1893","type":"journal-article","created":{"date-parts":[[2013,4,10]],"date-time":"2013-04-10T16:38:39Z","timestamp":1365611919000},"page":"158-167","source":"Crossref","is-referenced-by-count":28,"title":["Human Papillomavirus Detection"],"prefix":"10.1097","volume":"20","author":[{"given":"Jennifer","family":"Laudadio","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-4-20210202","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1016\/S0140-6736(11)61351-2","article-title":"Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis.","volume":"378","author":"Forouzanfar","year":"2011","journal-title":"Lancet"},{"key":"R2-4-20210202","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3322\/caac.20138","article-title":"Cancer statistics, 2012.","volume":"62","author":"Siegel","year":"2012","journal-title":"CA Cancer J Clin"},{"key":"R3-4-20210202","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.virol.2004.03.033","article-title":"Classification of papillomaviruses.","volume":"324","author":"de Villiers","year":"2004","journal-title":"Virology"},{"key":"R4-4-20210202","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S1470-2045(09)70096-8","article-title":"A review of human carcinogenspart B: biological agents.","volume":"10","author":"Bouvard","year":"2009","journal-title":"Lancet Oncol"},{"key":"R5-4-20210202","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1093\/jnci\/dji187","article-title":"The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice.","volume":"97","author":"Khan","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"R6-4-20210202","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1093\/jnci\/djq356","article-title":"Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistance.","volume":"102","author":"Kjaer","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"R8-4-20210202","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/nrc798","article-title":"Papillomaviruses and cancer: from basic studies to clinical application.","volume":"2","author":"zur Hausen","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"R9-4-20210202","doi-asserted-by":"crossref","first-page":"18411","DOI":"10.1016\/S0021-9258(18)55073-0","article-title":"The papillomavirus E2 regulatory proteins.","volume":"266","author":"McBride","year":"1991","journal-title":"J Biol Chem"},{"key":"R10-4-20210202","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1126\/science.2157286","article-title":"Association of human papillomavirus types 16 and 18 E6 proteins with p53.","volume":"248","author":"Werness","year":"1990","journal-title":"Science"},{"key":"R11-4-20210202","doi-asserted-by":"crossref","first-page":"6237","DOI":"10.1128\/JVI.66.10.6237-6241.1992","article-title":"Human papillomavirus type 16 E6 increases the degradation rate of p53 in human keratinocytes.","volume":"66","author":"Hubbert","year":"1992","journal-title":"J Virol"},{"key":"R12-4-20210202","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/380079a0","article-title":"Telomerase activation by the E6 gene product of human papillomavirus type 16.","volume":"380","author":"Klingelhutz","year":"1996","journal-title":"Nature"},{"key":"R13-4-20210202","first-page":"4620","article-title":"E7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway.","volume":"56","author":"Boyer","year":"1996","journal-title":"Cancer Res"},{"key":"R14-4-20210202","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1126\/science.2537532","article-title":"The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product.","volume":"243","author":"Dyson","year":"1989","journal-title":"Science"},{"key":"R15-4-20210202","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1101\/gad.11.16.2090","article-title":"Inhibition of CDK activity and PCNA-dependent DNA replication by p21 is blocked by interaction with the HPV-16 E7 oncoprotein.","volume":"11","author":"Funk","year":"1997","journal-title":"Genes Dev"},{"key":"R16-4-20210202","first-page":"2323","article-title":"Inactivation of the cdk inhibitor p27KIP1 by the human papillomavirus type 16 E7 oncoprotein.","volume":"13","author":"Zerfass-Thome","year":"1996","journal-title":"Oncogene"},{"key":"R18-4-20210202","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1086\/657321","article-title":"Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings.","volume":"202","author":"Bruni","year":"2010","journal-title":"J Infect Dis"},{"key":"R19-4-20210202","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1086\/587698","article-title":"Type-specific duration of human papillomavirus infection: implications for human papillomavirus screening and vaccination.","volume":"197","author":"Trottier","year":"2008","journal-title":"J Infect Dis"},{"key":"R20-4-20210202","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1086\/341782","article-title":"Incidence, prevalence, and clearance of type-specific human papillomavirus infections: the young womens health study.","volume":"186","author":"Giuliano","year":"2002","journal-title":"J Infect Dis"},{"key":"R21-4-20210202","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S1473-3099(07)70158-5","article-title":"Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis.","volume":"7","author":"de Sanjose","year":"2007","journal-title":"Lancet Infect Dis"},{"key":"R22-4-20210202","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/sj.bjc.6605747","article-title":"Multi-site study of HPV type-specific prevalence in women with cervical cancer, intraepithelial neoplasia and normal cytology, in England.","volume":"103","author":"Howell-Jones","year":"2010","journal-title":"Br J Cancer"},{"key":"R23-4-20210202","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/S0140-6736(05)67069-9","article-title":"Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis.","volume":"366","author":"Clifford","year":"2005","journal-title":"Lancet"},{"key":"R24-4-20210202","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1158\/1055-9965.EPI-10-0424","article-title":"Prospective study of human papillomavirus (HPV) types, HPV persistence, and risk of squamous cell carcinoma of the cervix.","volume":"19","author":"Sundstrom","year":"2010","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"R25-4-20210202","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1093\/jnci\/91.11.954","article-title":"Detection of human papillomavirus DNA in cytologically normal women and subsequent squamous intraepithelial lesions.","volume":"91","author":"Liaw","year":"1999","journal-title":"J Natl Cancer Inst"},{"key":"R26-4-20210202","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1017\/S0950268811000720","article-title":"Age factor and implication of human papillomavirus type-specific prevalence in women with normal cervical cytology.","volume":"140","author":"Lai","year":"2012","journal-title":"Epidemiol Infect"},{"key":"R27-4-20210202","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1086\/516784","article-title":"A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low grade squamous intraepithelial neoplasia.","volume":"195","author":"Plummer","year":"2007","journal-title":"J Infect Dis"},{"key":"R28-4-20210202","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1093\/jnci\/djn044","article-title":"Rapid clearance of human papillomavirus and implications for clinical focus on persistant infections.","volume":"100","author":"Rodriguez","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"R30-4-20210202","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1093\/infdis\/jiq116","article-title":"Long-term persistence of prevalently detected human papillomavirus infections in the absence of detectable cervical precancer and cancer.","volume":"203","author":"Castle","year":"2011","journal-title":"J Infect Dis"},{"key":"R31-4-20210202","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1093\/jnci\/djq001","article-title":"Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 23: critical role of duration of infection.","volume":"102","author":"Rodriguez","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"R32-4-20210202","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1093\/jnci\/djr283","article-title":"Persistence of type-specific human papillomavirus infection and increased long-term risk of cervical cancer.","volume":"103","author":"Chen","year":"2011","journal-title":"J Natl Cancer Inst"},{"issue":"suppl 3","key":"R33-4-20210202","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1016\/j.vaccine.2006.05.026","article-title":"Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases.","volume":"24","author":"Clifford","year":"2006","journal-title":"Vaccine"},{"key":"R34-4-20210202","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S1470-2045(10)70230-8","article-title":"Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study.","volume":"11","author":"de Sanjose","year":"2010","journal-title":"Lancet Oncol"},{"key":"R35-4-20210202","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa021641","article-title":"Epidemiologic classification of human papillomavirus types associated with cervical cancer.","volume":"348","author":"Munoz","year":"2003","journal-title":"N Engl J Med"},{"issue":"suppl 10","key":"R36-4-20210202","doi-asserted-by":"crossref","first-page":"K1","DOI":"10.1016\/j.vaccine.2008.05.064","article-title":"Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia.","volume":"26","author":"Bosch","year":"2008","journal-title":"Vaccine"},{"key":"R37-4-20210202","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S1470-2045(11)70145-0","article-title":"Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice.","volume":"12","author":"Katki","year":"2011","journal-title":"Lancet Oncol"},{"key":"R38-4-20210202","doi-asserted-by":"crossref","first-page":"a1754","DOI":"10.1136\/bmj.a1754","article-title":"Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study.","volume":"337","author":"Dillner","year":"2008","journal-title":"BMJ"},{"key":"R39-4-20210202","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1158\/1055-9965.EPI-11-0206","article-title":"A long-term prospective study of type-specific human papillomavirus infection and risk of cervical neoplasia among 20,000 women in the Portland Kaiser Cohort Study.","volume":"20","author":"Schiffman","year":"2011","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"R40-4-20210202","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1309\/AJCPTGD94EVRSJCG","article-title":"American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer.","volume":"137","author":"Saslow","year":"2012","journal-title":"Am J Clin Pathol"},{"key":"R41-4-20210202","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.ajog.2007.07.047","article-title":"2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests.","volume":"197","author":"Wright","year":"2007","journal-title":"Am J Obstet Gynecol"},{"key":"R43-4-20210202","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1001\/jama.297.8.813","article-title":"Prevalence of HPV infection among females in the United States.","volume":"297","author":"Dunne","year":"2007","journal-title":"JAMA"},{"key":"R44-4-20210202","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ajog.2004.01.043","article-title":"Diagnoses and outcomes in cervical cancer screening: a population-based study.","volume":"191","author":"Insinga","year":"2004","journal-title":"Am J Obstet Gynecol"},{"key":"R45-4-20210202","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1309\/AJCPZ5JY6FCVNMOT","article-title":"High-risk human papillomavirus testing in women with ASC-US cytology: results from the ATHENA HPV study.","volume":"135","author":"Stoler","year":"2011","journal-title":"Am J Clin Pathol"},{"key":"R46-4-20210202","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1097\/01.AOG.0000263461.71732.40","article-title":"Risk of precancer and follow-up management strategies for women with human papillomavirus-negative atypical squamous cells of undetermined significance.","volume":"109","author":"Safaeian","year":"2007","journal-title":"Obstet Gynecol"},{"key":"R47-4-20210202","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1067\/mob.2003.461","article-title":"Prospective follow-up suggests similar risk of subsequent cervical intraepithelial neoplasia grade 2 or 3 among women with cervical intraepithelial neoplasia grade 1 or negative colposcopy and directed biopsy.","volume":"188","author":"Cox","year":"2003","journal-title":"Am J Obstet Gynecol"},{"key":"R48-4-20210202","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1002\/ijc.22527","article-title":"Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update.","volume":"121","author":"Smith","year":"2007","journal-title":"Int J Cancer"},{"key":"R50-4-20210202","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S1470-2045(09)70360-2","article-title":"Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial.","volume":"11","author":"Ronco","year":"2010","journal-title":"Lancet Oncol"},{"key":"R51-4-20210202","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1056\/NEJMoa073204","article-title":"Human papillomavirus and Papanicolaou tests to screen for cervical cancer.","volume":"357","author":"Naucler","year":"2007","journal-title":"N Engl J Med"},{"key":"R52-4-20210202","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1002\/ijc.21955","article-title":"Overview of the European and North American studies on HPV testing in primary cervical cancer screening.","volume":"119","author":"Cuzick","year":"2006","journal-title":"Int J Cancer"},{"key":"R53-4-20210202","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1309\/AJCPTUS5EXAS6DKZ","article-title":"Evaluation of HPV-16 and HPV-18 genotyping for the triage of women with high-risk HPV cytology-negative results.","volume":"136","author":"Wright","year":"2011","journal-title":"Am J Clin Pathol"},{"key":"R54-4-20210202","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1002\/cncr.21664","article-title":"Distribution of human papillomavirus types in ThinPrep Papanicolaou tests classified according to the Bethesda 2001 terminology and correlations with patient age and biopsy outcome.","volume":"106","author":"Evans","year":"2006","journal-title":"Cancer"},{"key":"R55-4-20210202","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/cncr.22488","article-title":"Testing for HPV as an objective measure for quality assurance in gynecologic cytology: positive rates in equivocal and abnormal specimens and comparison with the ASCUS to SIL ratio.","volume":"111","author":"Ko","year":"2007","journal-title":"Cancer"},{"issue":"suppl 3","key":"R56-4-20210202","doi-asserted-by":"crossref","first-page":"S78","DOI":"10.1016\/j.vaccine.2006.05.117","article-title":"Chapter 9: clinical applications of HPV testing: a summary of meta-analyses.","volume":"24","author":"Arbyn","year":"2006","journal-title":"Vaccine"},{"key":"R57-4-20210202","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1093\/jnci\/djj009","article-title":"Cost-effectiveness analysis based on the atypical squamous cells of undetermined significancelow-grade squamous intraepitheial lesion triage study (ALTS).","volume":"98","author":"Kulasingam","year":"2006","journal-title":"J Natl Cancer Inst"},{"key":"R58-4-20210202","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1309\/RNF3C01JKADQCLKP","article-title":"The expanded use of HPV testing in gynecologic practice per ASCCP-guided management requires the use of well validated assays.","volume":"127","author":"Stoler","year":"2007","journal-title":"Am J Clin Pathol"},{"key":"R60-4-20210202","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1128\/JCM.38.2.651-655.2000","article-title":"Comparison of human papillomavirus detection and typing by cycle sequencing, line blotting, and hybrid capture.","volume":"38","author":"Vernon","year":"2000","journal-title":"J Clin Microbiol"},{"key":"R61-4-20210202","first-page":"1394","article-title":"Restricted cross-reactivity of hybrid capture 2 with nononcogenic human papillomavirus types.","volume":"11","author":"Castle","year":"2002","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"suppl 1","key":"R62-4-20210202","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1016\/S1386-6532(09)70010-1","article-title":"Analytical performance of the Investigational Use Only Cervista HPV HR test as determined by a multi-center study.","volume":"45","author":"Day","year":"2009","journal-title":"J Clin Virol"},{"issue":"suppl 1","key":"R64-4-20210202","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1016\/S1386-6532(09)70007-1","article-title":"Analytical characterization of the APTIMA HPV Assay.","volume":"45","author":"Dockter","year":"2009","journal-title":"J Clin Virol"},{"key":"R67-4-20210202","doi-asserted-by":"crossref","first-page":"3983","DOI":"10.1128\/JCM.05552-11","article-title":"Clinical validation of the cobas 4800 HPV test for cervical screening purposes.","volume":"49","author":"Heideman","year":"2011","journal-title":"J Clin Microbiol"},{"key":"R68-4-20210202","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/S1470-2045(11)70188-7","article-title":"Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.","volume":"12","author":"Castle","year":"2011","journal-title":"Lancet Oncol"},{"key":"R69-4-20210202","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1001\/jama.285.11.1500","article-title":"Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL triage study.","volume":"285","author":"Stoler","year":"2001","journal-title":"JAMA"},{"key":"R70-4-20210202","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1309\/84E5WHJQHK83BGQD","article-title":"Reproducibility of HPV DNA testing by hybrid capture 2 in a screening setting.","volume":"124","author":"Carozzi","year":"2005","journal-title":"Am J Clin Pathol"},{"key":"R71-4-20210202","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jviromet.2012.05.023","article-title":"The diagnostic performance of classical molecular tests used for detecting human papillomaviruses.","volume":"185","author":"Munoz","year":"2012","journal-title":"J Virol Methods"},{"key":"R73-4-20210202","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1002\/ijc.24010","article-title":"Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older.","volume":"124","author":"Meijer","year":"2009","journal-title":"Int J Cancer"},{"key":"R74-4-20210202","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1309\/AJCPKA6ATAPBZ6JQ","article-title":"A population-based clinical trial comparing endocervical high-risk HPV testing using hybrid capture 2 and Cervista from the SHENCCAST II study.","volume":"135","author":"Belinson","year":"2011","journal-title":"Am J Clin Pathol"},{"key":"R75-4-20210202","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jmoldx.2011.09.005","article-title":"Analytical comparison of the cobas HPV test with hybrid capture 2 for the detection of high-risk HPV genotypes.","volume":"14","author":"Lindemann","year":"2012","journal-title":"J Mol Diagn"},{"issue":"suppl 1","key":"R76-4-20210202","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1016\/S1386-6532(09)70009-5","article-title":"Clinical performance of the APTIMA HPV Assay for the detection of high-risk HPV and high-grade cervical lesions.","volume":"45","author":"Dockter","year":"2009","journal-title":"J Clin Virol"},{"key":"R77-4-20210202","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1128\/JCM.01674-10","article-title":"Performance of the APTIMA high-risk human papillomavirus mRNA assay in a referral population in comparison with hybrid capture 2 and cytology.","volume":"49","author":"Clad","year":"2011","journal-title":"J Clin Microbiol"},{"key":"R78-4-20210202","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1002\/ijc.25726","article-title":"Evaluation of oncogenic human papillomavirus RNA and DNA tests with liquid-based cytology in primary cervical cancer screening: the FASE study.","volume":"129","author":"Monsonego","year":"2011","journal-title":"Int J Cancer"},{"issue":"suppl 1","key":"R79-4-20210202","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1016\/S1386-6532(09)70008-3","article-title":"Efficiency of the APTIMA HPV Assay for detection of HPV RNA and DNA targets.","volume":"45","author":"Getman","year":"2009","journal-title":"J Clin Virol"},{"key":"R80-4-20210202","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.ygyno.2011.07.024","article-title":"Comparison of different commercial methods for HPV detection in follow-up cytology after ASCUSLSIL prediction of CIN2-3 in follow up biopsies and spontaneous regression of CIN2-3.","volume":"123","author":"Ovestad","year":"2011","journal-title":"Gynecol Oncol"},{"key":"R81-4-20210202","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1128\/JCM.05400-11","article-title":"Comparison of the hybrid capture 2 and cobas 4800 tests for detection of high-risk human papillomavirus in specimens collected in PreservCyt medium.","volume":"50","author":"Wong","year":"2012","journal-title":"J Clin Microbiol"},{"key":"R82-4-20210202","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1128\/JCM.00181-12","article-title":"Comparison of seven tests for high-grade cervical intraepithelial neoplasia in women with abnormal smears: the Predictors 2 study.","volume":"50","author":"Szarewski","year":"2012","journal-title":"J Clin Microbiol"},{"key":"R83-4-20210202","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S1470-2045(08)70208-0","article-title":"Use of p16-INK4A overexpression to increase the specificity of human papillomavirus testing: a nested substudy of the NTCC randomised controlled trial.","volume":"9","author":"Carozzi","year":"2008","journal-title":"Lancet Oncol"}],"container-title":["Advances in Anatomic Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PAP.0b013e31828d1893","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T04:41:55Z","timestamp":1620967315000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00125480-201305000-00004"}},"subtitle":["Testing Methodologies and Their Clinical Utility in Cervical Cancer Screening"],"short-title":[],"issued":{"date-parts":[[2013,5]]},"references-count":73,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/pap.0b013e31828d1893","relation":{},"ISSN":["1072-4109"],"issn-type":[{"value":"1072-4109","type":"print"}],"subject":[],"published":{"date-parts":[[2013,5]]}}}